Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Summary of Research: Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US
Saved in:
| Published in: | Ophthalmology and Therapy |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1867301677750550528 |
|---|---|
| collection | WordPress RSS FRELIP Feed Integration |
| container_title | Ophthalmology and Therapy |
| description | |
| discipline_display | Ophthalmology and Optometry |
| discipline_facet | Ophthalmology and Optometry |
| format | Online Article RSS Article |
| genre | Journal Article |
| id | rss_article:60980 |
| institution | FRELIP |
| journal_source_facet | Ophthalmology and Therapy |
| publishDate | 2026 |
| publishDateSort | 2026 |
| record_format | rss_article |
| spellingShingle | Summary of Research: Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US Ophthalmology and Optometry General Ophthalmology and Optometry |
| sub_discipline_display | General |
| sub_discipline_facet | General |
| subject_display | Ophthalmology and Optometry General Ophthalmology and Optometry Ophthalmology and Optometry General Ophthalmology and Optometry |
| subject_facet | Ophthalmology and Optometry General Ophthalmology and Optometry |
| title | Summary of Research: Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US |
| title_auth | Summary of Research: Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US |
| title_full | Summary of Research: Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US |
| title_fullStr | Summary of Research: Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US |
| title_full_unstemmed | Summary of Research: Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US |
| title_short | Summary of Research: Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US |
| title_sort | summary of research: economic benefit of aflibercept 8 mg versus faricimab for neovascular age-related macular degeneration or diabetic macular edema in the us |
| topic | Ophthalmology and Optometry General Ophthalmology and Optometry |
| url | https://link.springer.com/article/10.1007/s40123-026-01398-x |